In a similar trend to a known STAT3 inhibitor BP1-102, the lead compounds preferentially impaired viability in at least one of the STAT3-dependent breast or prostate cancer cell lines (Fig 5B). This evidence concerns the gene STAT3 and prostate carcinoma.